• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Improved treatment for sleeping sickness now available

Geneva, Switzerland / Kampala, Uganda — 22 Sep 2009
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

NECT  (Nifurtimox-Eflornithine Combination Therapy), the first new treatment in 25 years against Human African trypanosomiasis (HAT)  or sleeping sickness – is now available.  Endemic countries have now begun the process of ordering the new combination treatment and kits through the World Health Organization (WHO). Developed by DNDi and its partners, NECT cuts the cost of treatment by half and significantly reduces the burden on health workers. The announcement was made today at the International Scientific Council for Trypanosomiasi Research and Control (ISCTRC), in Kampala, Uganda.
[Français]

  • Read more about the NECT project

“Thanks to an innovative partnership and the hard work of health workers, researchers, and specialists from endemic countries, industry and academia, a new treatment is now available to treat one of the most neglected disease in Africa. Not only is this new therapy more adapted to patient needs in remote areas, but it also cuts the cost of drugs, hospitalisation and transport”, said Dr Bernard Pécoul, Executive Director of Drugs for Neglected Diseases initiative (DNDi).
Sleeping sickness threatens 60 million people in 36 countries across sub-Saharan Africa. Transmitted to humans by the tsetse fly, this neglected tropical disease is fatal without treatment. NECT is a new, combination treatment option for the advanced stage (stage 2) of HAT or sleeping sickness. This stage affects the patient’s central nervous system and causes neuropsychiatric problems, convulsions, and serious sleep disturbance; leading to coma and death.

In May 2009, NECT was added to the WHO list of Essential Medicines for the treatment of sleeping sickness.

NECT combination therapy consists of a simplified co-administration of oral nifurtimox, and injectible eflornithine. It reduces the total number of intravenous infusions of eflornithine from 56 to 14 and shortens hospitalisation from 14 days to 10, which makes treatment more convenient for patients. Because NECT only requires 2 infusions a day, administered during the daytime, this is easier for health workers and makes treatment far more suitable for remote and resource-poor settings where HAT is being treated.
Until now, health workers and patients had two main treatment options: 1) widely used ‘melarsoprol’, which is painful to inject, arsenic based and toxic, and kills an estimated 5 % of patients, and 2) the newer Eflornithine monotherapy, which requires one hour infusions, to be given every six hours for two weeks. Eflornithine monotherapy is better tolerated and more effective than Melarsoprol, but due to the high burden on health workers and the high cost of the medical equipment required to correctly administer it night and day, too many patients throughout Africa still continue to be treated with toxic Melarsoprol.

“As a doctor, you don’t treat someone to see them die, you treat them to see them go home”, said Dr. Constantin Miaka Bilenge, National Health Advisor, for DRC. “This new combination treatment is easier to use than eflornithine in monotherapy and brings hope for the patient and for the clinician, especially in countries like ours where the infrastructure has broken down.”
Treating patients with the new combination therapy now costs half as much as the existing, eflornithine monotherapy. With the NECT kits, the cost per patient of medicines, medical treatment and transport is halved to 223 Euros from 447 Euros for ‘eflornithine monotherapy’. Because the new treatment reduces the number of daily intravenous infusions and the length of treatment, it also reduces the cost of hospitalization and the burden on health staff in country.

“The availability of NECT improves the treatment of sleeping sickness and makes a big difference in terms of logistics, hospitalization, and cost”, said Dr Pere Simarro, Head of WHO sleeping sickness control and surveillance programme.”To support countries, WHO will make available, free of charge, kits which include the new treatment and all the medical equipment needed to treat patients in remote areas”.
WHO has made preparations for the arrival of NECT and is working to ensure health workers receive appropriate training. WHO has designed a kit in collaboration with Médecins Sans Frontières-Logistique that contains the medicine and all the equipment needed to correctly administer the treatment.

The kits are provided to countries free of charge through WHO1. It is hoped this will also help national control programmes to switch from toxic and painful Melarsoprol to better tolerated NECT.

Jacqueline Tong, Senior advocacy officer for Médecins Sans Frontières (MSF) added: “Until now, we have been losing patients because of toxic old drugs such as Melarsoprol, so we welcome and urgently need this new, safer and less complicated treatment to save lives from this fatal disease”.

Each 36 kg NECT kit contains four full treatments instead of two treatments with the eflornithine monotherapy. The volume per treatment is also reduced from 85 dm3 to 37.5 dm3. Less volume and less weight makes transport much easier and cheaper, especially to remote areas in places such as the DRC.
The development of NECT is the result of a six year collaborative partnership, coordinated by DNDi. Partners include, Médecins Sans Frontières, Epicentre, HAT platform, the Swiss Tropical Institute, the national control programmes from the Democratic Republic of the Congo (DRC) and Republic of Congo, with the support of the World Health Organization. The drugs were donated by sanofi-aventis and Bayer Schering Pharma AG.

For further information please contact: Samantha Bolton in Kampala on sbolton@dndi.org, on +256 78 44 55 381, Eva van Beek in Geneva on +41 (0)79 882 44 70.  Still and video images are also available. www.dndi.org

###Editor Notes###

The Drugs for Neglected Diseases initiative (DNDi) is an independent, not-for-profit product development partnership working to research and develop new and improved treatments for neglected diseases such as malaria, leishmaniasis, human African trypanosomiasis, and Chagas disease. With the objective to address unmet patient needs for these diseases, DNDi was established in 2003 by Institut Pasteur and Médecins Sans Frontières along with four publicly-funded research organizations in neglected disease-endemic countries. Working in partnership with industry and academia, DNDi has the largest ever R&D portfolio for the kinetoplastid diseases and currently has 3 post-registration, 9 clinical, and 4 preclinical projects, along with a wide variety of discovery activities. In 2007 and 2008, DNDi has delivered its first two products, fixed-dose antimalarial “ASAQ” and “ASMQ”. This year, the safe and effective treatment for the advanced stage of sleeping sickness NECT (nifurtimox-eflornithine combination therapy), has been added to the Essential Medicines List (EML) of the World Health Organization WHO. For further information, please consult www.dndi.org.

Background on NECT

1) Since the beginning of the 20th century, medicines and treatment for sleeping sickness, TB and leprosy have traditionally always been provided for free to patients throughout Africa. Because sleeping sickness affects the poorest of the poor and requires hospitalization, treatment cannot be purchased over the counter and is managed through specialized national control programmes.

Sleeping sickness

Read, watch, share

Loading...
Woman standing in front of a house
Press releases
2 Feb 2023

Dutch government renews support to DNDi projects on poverty-related diseases that disproportionately impact women

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Young man sitting in hospital setting
News
30 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo